CLEVELAND, Aug. 5 /PRNewswire/ — JumpStart
Ventures, which invests in and partners with innovative,
early-stage companies in Northeast
Ohio, announced an investment commitment of $250,000 in drug development company
ChanRx. The two-year-old company is developing a pharmaceutical
compound to treat atrial fibrillation, a heart condition that
affects two million Americans, with 200,000 new cases being
diagnosed each year.
(Logo:
http://www.newscom.com/cgi-bin/prnh/20060209/CLJUMPSTARTLOGO
)
(Logo: http://photos.prnewswire.com/prnh/20060209/CLJUMPSTARTLOGO
)
Atrial fibrillation is characterized by an irregular beating of
the heart caused by misfiring of electrical impulses. The abnormal
contracting causes decreased cardiac function, raising the risk of
stroke and heart failure. An oral form of ChanRx’s anti-arrhythmia
drug, called Vanoxerine, has already demonstrated its ability to
restore normal heart rhythm in a human clinical study. The study
also showed an improved safety
‘/>”/>
SOURCE